Serotonin

Persistent flushing, watery diarrhea, or unexplained wheezing can sometimes lead to a workup for a hormone-producing neuroendocrine tumor. These symptoms have many other causes. Urinary serotonin can provide an additional clue in selected cases, especially when a tumor releases serotonin's precursor, but the better-established biochemical test for carcinoid syndrome is 5-HIAA.

The distinction between tests matters here. Much of the tumor research used 24-hour urine collections, older laboratory methods, or blood measurements. Those studies do not establish the diagnostic accuracy of this particular LC-MS result reported in mcg/g. Using it to assess mood, memory, stress, or healthy aging remains exploratory.

Where Urinary Serotonin Comes From

Your body makes serotonin from tryptophan, which is supplied by dietary protein. Most of your body's serotonin is produced in the gut lining. It helps regulate gut movement and also carries signals between nerve cells.

Platelets take up serotonin from the blood and store it. Platelets are the small cell fragments that help blood clot. Serotonin is broken down largely in the liver and lungs, producing 5-hydroxyindoleacetic acid, usually shortened to 5-HIAA.

Urinary serotonin has more than one source. Some comes from serotonin circulating outside platelets, and some is made in the kidneys from 5-hydroxytryptophan, or 5-HTP. This makes the result more complicated than a measure of how much serotonin your gut releases.

The brain makes its own serotonin, and serotonin in the blood does not readily enter the brain. Urinary serotonin therefore cannot establish a brain serotonin deficiency or measure depression, happiness, or stress.

What This Measurement Reports

This test measures serotonin itself in urine using liquid chromatography with mass spectrometry, or LC-MS. The method separates chemicals before detecting their mass-related signals. It is different from measuring serotonin in blood or measuring its breakdown product 5-HIAA. LC-MS still requires validation for interference, sample handling, and accurate calibration.

Hormone-Producing Tumors

Neuroendocrine tumors arise from cells that release hormones or other chemical signals. Some release enough serotonin and other substances to cause carcinoid syndrome. Diarrhea, flushing, and wheezing can occur, and sustained serotonin exposure can contribute to scarring of the heart's valves.

For intestinal tumors, the liver usually breaks down secreted serotonin before it reaches the rest of the circulation. Carcinoid syndrome therefore commonly appears after spread to the liver, although tumors in other locations can release their products directly into the wider circulation. A tumor's size, location, and secretion pattern all affect whether a biochemical marker changes.

Historical studies support a limited role for urinary serotonin. They also show why results from different specimens should not be treated as interchangeable.

These results came from particular study populations and collection methods. The 64% detection rate cannot be assigned to this test, and the comparison groups do not establish how often an unexpected result in a healthy person represents cancer. A result within the laboratory's reference interval cannot exclude a tumor.

Why Serotonin and 5-HIAA Can Disagree

Some tumors release 5-HTP because they do not efficiently complete serotonin production. The kidneys can convert that precursor into serotonin, producing a urinary serotonin increase without a matching 5-HIAA increase. This has been described in tumors arising in the upper digestive tract or lungs, but the pattern alone cannot diagnose a tumor or establish its location.

Heart Valves and Survival

Much of the evidence connecting serotonin production to prognosis concerns 24-hour urinary 5-HIAA, a related but different measurement. A pooled analysis of 12 studies involving 755 people with neuroendocrine tumors associated higher 5-HIAA with higher one-year mortality. It does not provide a mortality prediction from an intact urinary serotonin result.

Research on carcinoid heart disease has also used blood serotonin and urinary 5-HIAA. In a database of 604 people with carcinoid tumors, these measurements were higher in those with valve disease. Later studies supported NT-proBNP as a useful blood marker of heart strain alongside heart imaging. None establishes this urine serotonin result as a substitute for an echocardiogram.

Alzheimer's Disease and Memory

A study analyzing 556 urine samples found lower urinary serotonin in people with Alzheimer's disease than in healthy controls or people with mild cognitive impairment. The urine analysis used research mass-spectrometry profiling normalized to creatinine, which is not the same as a validated diagnostic interpretation for this assay.

The study also examined whether people with mild cognitive impairment later developed Alzheimer's disease. Baseline measurements did not distinguish those who progressed from those who remained stable. Inflammation and altered tryptophan processing were proposed explanations for the findings, not demonstrated causes. A low urine result does not diagnose Alzheimer's disease or predict memory decline.

Pregnancy and Blood Sugar

A small gestational-diabetes study found higher urinary serotonin using direct-infusion mass spectrometry, which differs from this test's LC-MS method. Its combined blood-and-urine prediction model was developed in only 21 participants and lacked independent validation. This finding has no established role in diagnosing gestational diabetes or choosing treatment.

Gut Symptoms Without a Tumor

Studies of irritable bowel syndrome and chronic constipation have found differences in urinary 5-HIAA and other tryptophan breakdown products. These are different molecules from intact serotonin. The findings do not establish urinary serotonin as a way to diagnose these conditions, identify a gut-bacteria imbalance, or select a treatment.

Mood, Stress, and Parkinson's Disease

In a study of 41 people with Parkinson's disease and 20 controls, urinary serotonin did not differ significantly between groups. A separate study of 100 workers found that urinary serotonin alone did not distinguish the groups with higher and lower questionnaire-based stress scores. Its exploratory combined-marker score does not validate serotonin as an individual stress test.

When Results Can Be Misleading

• Food can change urinary serotonin. A controlled study in 15 healthy adults found that a serotonin-rich diet increased urinary serotonin measured in 24-hour collections. An earlier banana experiment with no change does not establish that the test is unaffected by diet.
• Medications can affect results biologically. Selective serotonin reuptake inhibitors, or SSRIs, can lower serotonin measurements; some other medicines can raise them. A study finding no difference in urine serotonin by antidepressant use does not rule out interference in an individual result.
• Kidney function can affect serotonin production and excretion. If the result is divided by urine creatinine, differences in muscle mass and creatinine excretion also influence the ratio. Creatinine adjustment reduces dilution effects but does not remove every source of variation.
• Storage and preservation requirements depend on the assay. A sample handled outside the laboratory's validated conditions may give an unreliable result.
• LC-MS can be affected by other substances in urine and by compounds that produce overlapping signals. One clinical LC-MS/MS assay reports falsely elevated urinary serotonin with heavy nicotine exposure because of interference from cotinine. Whether that interference applies to this assay requires laboratory confirmation.

What a Trend Can Mean

For an established serotonin-secreting tumor, a marker that was informative at diagnosis may contribute to follow-up alongside symptoms, other biochemical measurements, and imaging. A change can reflect altered secretion as well as altered tumor burden. The cited evidence does not establish that serial testing in healthy people improves prevention or longevity.